Edition:
United States

Geron Corp (GERN.O)

GERN.O on Nasdaq

2.18USD
20 Sep 2017
Change (% chg)

-- (--)
Prev Close
$2.18
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,238,226
52-wk High
$3.15
52-wk Low
$1.81

Chart for

About

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry,... (more)

Overall

Beta: 2.77
Market Cap(Mil.): $347.09
Shares Outstanding(Mil.): 159.21
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 78.94 16.33
EPS (TTM): -- -- --
ROI: -- 2.84 14.66
ROE: -- 4.61 13.99

BRIEF-Geron Q2 loss per share $0.04

* Geron Corporation reports second quarter 2017 financial results

Aug 09 2017

BRIEF-Geron provides updates to imetelstat clinical development

* Expects imbark protocol-specified primary analysis to begin no later than q3 of 2018 Source text for Eikon: Further company coverage:

Jul 31 2017

BRIEF-Geron Q1 loss per share $0.05

* Geron Corporation reports first quarter 2017 financial results and recent events

May 09 2017

BRIEF-Geron Corp and Janssen Research & Development LLC has completed second internal data reviews of Imerge and Imbark

* Geron Corp - Janssen Research & Development, LLC has completed second internal data reviews of Imerge and Imbark

Apr 10 2017

Earnings vs. Estimates